In-vitro Study Shows Ozenoxacin Effective Against Drug-Resistant Skin Infection Bacteria
A laboratory study found that ozenoxacin, a novel topical antibiotic, demonstrated potent activity against Staphylococcus aureus and Streptococcus pyogenes isolates, including drug-resistant strains. The research tested ozenoxacin against 109 S. aureus and 24 S. pyogenes clinical isolates using standard microdilution methods, comparing it to nine other antibiotics. The findings suggest ozenoxacin could be a useful treatment option for skin and soft-tissue infections as antibiotic resistance to existing topical agents increases.
Researchers conducted an in-vitro evaluation of ozenoxacin, a non-fluorinated topical quinolone antibiotic, against clinical isolates of Staphylococcus aureus and Streptococcus pyogenes collected from skin, soft-tissue, wound, abscess, and blood sources. The study tested 109 methicillin-susceptible and methicillin-resistant S. aureus strains and 24 S. pyogenes isolates using the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. Ozenoxacin demonstrated potent activity against all tested strains, with minimum inhibitory concentrations (MIC50/90) of 0.125/0.5 μg/ml for S. aureus and 0.015/0.03 μg/ml for S. pyogenes. When compared to nine other agents including vancomycin and linezolid, ozenoxacin showed superior activity against S. aureus isolates, with lower MIC90 values than eight of the comparator drugs. The researchers concluded that these laboratory findings support ozenoxacin's potential as an effective first-in-class topical quinolone for treating various skin and soft-tissue infections.
Limitations & open questions
The study is limited to in-vitro laboratory testing and does not include clinical trial data demonstrating efficacy or safety in human patients. The authors do not discuss potential limitations such as the generalizability of results across different geographic regions, the prevalence of resistance mechanisms in the tested isolates, or how in-vitro activity translates to clinical outcomes.
What different sources said
- bioRxivCenter
In-vitro evaluation of Ozenoxacin and other Antibiotics against Staphylococcus aureus and Streptococcus pyogenes isolated from Skin and Soft Tissue Infections
Related
Profilin-1 Deficiency Activates Immune Response Against Breast Cancer in Preclinical Study
Researchers found that removing the Profilin-1 protein from breast cancer cells triggers DNA damage and activates an immune pathway called STING, which recruits cancer-fighting T cells and causes tumor regression in mice. The study used CRISPR gene-editing technology to deplete Profilin-1 and observed that the resulting genomic instability paradoxically strengthens anti-tumor immunity. The findings suggest targeting Profilin-1 could be a new strategy to enhance immunotherapy effectiveness in breast cancer.
Computational Study Explores How Magnetic Fields May Affect Tomato Plant Ion Channels
Researchers used molecular dynamics simulations to investigate how static magnetic fields affect the CNGC6 ion channel in tomato plants, finding that magnetic fields may alter the channel's structure in specific ways. The study was motivated by observations that magnetic treatment of tomato seeds appears to speed germination and improve plant development, though the underlying cellular mechanisms remain unclear. The findings provide a computational foundation for future experimental work, though the authors emphasize this is a preliminary exploratory study requiring validation.
New Algorithm Simplifies Evolutionary Network Reconstruction for Hybridized Species
Researchers developed NetCS, a fast algorithm for reconstructing evolutionary networks in hybridized species that avoids expensive computational bottlenecks. The method works well when given accurate intermediate data but reveals that the real challenge in network inference lies in an earlier reconstruction step. This finding could enable phylogenetic analyses of larger datasets while identifying where future improvements are needed.